Literature DB >> 12603413

Clinical management of prostatic intraepithelial neoplasia as diagnosed by extended needle biopsies.

I F San Francisco1, A F Olumi, J Kao, S Rosen, W C DeWolf.   

Abstract

OBJECTIVE: To examine the results of the clinical management of patients with high-grade prostatic intraepithelial neoplasia (PIN), as diagnosed by extended needle biopsies. PATIENTS AND METHODS: The clinical data were reviewed from a cohort of 387 men who underwent > or = 10 core prostate needle biopsies between 1 January 1996 and 31 December 1997 by one urologist (W.C.D.). Two study groups were identified; the first comprised 47 patients with only high-grade PIN and the second was a control group of 137 patients with only benign findings on their biopsies. Those patients with cancer, atypia or a prostatic biopsy with fewer than 10 cores were excluded. The clinical and histological data were evaluated. The criteria for re-biopsy were two successive increases in prostate specific antigen (PSA) level or any change in the findings on digital rectal examination (DRE). All patients were monitored at 6-12 month intervals.
RESULTS: Of the 387 patients, 46% had normal findings, 5.2% had atypia, 12.6% had PIN alone, 15 (3.9%) had PIN plus atypia, 6.7% had PIN plus cancer and 32.3% had cancer. There was no significant difference between the PIN and control groups in age, DRE, PSA level, prostate size (by ultrasonography), free testosterone level, number of the cores and time of follow-up (median 34.8 and 36.6 months for the PIN and control groups, respectively). Of the PIN and control groups, 21 (45%) and 43 (31%) respectively had at least one re-biopsy. Five patients (24%) in the PIN and one (2.3%) in the control group developed cancer (P = 0.0124). All these patients had organ-confined disease and were found to have either Gleason scores 3 + 3 or 3 + 4 on surgical specimens. There was no correlation between the original location of PIN and the location of subsequent malignancy.
CONCLUSIONS: Patients with one set of extended needle biopsies with high-grade PIN should be followed clinically every 6-12 months, and it may be safe to reserve repeat biopsy for those with changes in PSA level and/or in the DRE.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12603413     DOI: 10.1046/j.1464-410x.2003.04081.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  10 in total

1.  Initial high-grade prostatic intraepithelial neoplasia with carcinoma on subsequent prostate needle biopsy: findings at radical prostatectomy.

Authors:  Turki O Al-Hussain; Jonathan I Epstein
Journal:  Am J Surg Pathol       Date:  2011-08       Impact factor: 6.394

Review 2.  Precursor lesions to prostatic adenocarcinoma.

Authors:  Jonathan I Epstein
Journal:  Virchows Arch       Date:  2008-12-02       Impact factor: 4.064

3.  [Laryngeal epithelial dysplasia vs. laryngeal intraepithelial neoplasia].

Authors:  T Dreyer; H Glanz
Journal:  Pathologe       Date:  2004-02       Impact factor: 1.011

4.  High-grade prostatic intraepithelial neoplasia and atypical small acinar proliferation on initial 21-core extended biopsy scheme: incidence and implications for patient care and surveillance.

Authors:  Guillaume Ploussard; Gwendoline Plennevaux; Yves Allory; Laurent Salomon; Sandy Azoulay; Dimitri Vordos; Andreas Hoznek; Claude-Clément Abbou; Alexandre de la Taille
Journal:  World J Urol       Date:  2009-04-17       Impact factor: 4.226

5.  Subsequent prostate cancer detection in patients with prostatic intraepithelial neoplasia or atypical small acinar proliferation.

Authors:  Moamen M Amin; Suganthiny Jeyaganth; Nader Fahmy; Louis Bégin; Samuel Aronson; Stephen Jacobson; Simon Tanguay; Armen G Aprikian
Journal:  Can Urol Assoc J       Date:  2007-09       Impact factor: 1.862

Review 6.  Dealing with non-cancerous findings on prostate biopsy.

Authors:  Timothy C Brand; Gregory P Thibault; Joseph W Basler
Journal:  Curr Urol Rep       Date:  2006-05       Impact factor: 2.862

7.  Periostin identified as a potential biomarker of prostate cancer by iTRAQ-proteomics analysis of prostate biopsy.

Authors:  Guowei Xia; Qiang Ding; Chuanyu Sun; Chao Song; Zhicheng Ma; Ke Xu; Yang Zhang; Hong Jin; Shijun Tong; Weihong Ding
Journal:  Proteome Sci       Date:  2011-04-19       Impact factor: 2.480

8.  Atypical small acinar proliferation and two or more cores of high-grade intraepithelial neoplasia on a previous prostate biopsy are significant predictors of cancer during a transperineal template-guided saturation biopsy aimed at sampling one core for each 1 mL of prostate volume.

Authors:  Yasushi Nakai; Nobumichi Tanaka; Makito Miyake; Shunta Hori; Yoshihiro Tatsumi; Yosuke Morizawa; Tomomi Fujii; Noboru Konishi; Kiyohide Fujimoto
Journal:  Res Rep Urol       Date:  2017-09-21

9.  Prostate Cancer Chemoprevention Targeting Men with High-Grade Prostatic Intraepithelial Neoplasia (HGPIN) and Atypical Small Acinar Proliferation (ASAP): Model for Trial Design and Outcome Measures.

Authors:  Nagi Kumar; Theresa Crocker; Tiffany Smith; Shahnjayla Connors; Julio Pow-Sang; Philippe E Spiess; Kathleen Egan; Gwen Quinn; Michael Schell; Said Sebti; Aslam Kazi; Tian Chuang; Raoul Salup; Mohamed Helal; Gregory Zagaja; Edouard Trabulsi; Jerry McLarty; Tajammul Fazili; Christopher R Williams; Fred Schreiber; Kyle Anderson
Journal:  J Clin Trials       Date:  2012-01-21

10.  Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention.

Authors:  Nagi Kumar; Ganna Chornokur
Journal:  Transl Med (Sunnyvale)       Date:  2012-12-31
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.